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Updated Meta-Analysis of Randomized Trials
Massimiliano Fusaro, MD,* Salvatore Cassese, MD,* Gjin Ndrepepa, MD,*
Gunnar Tepe, MD,y Lamin King, MD,* Ilka Ott, MD,* Mateja Nerad, MD,z
Heribert Schunkert, MD,*x Adnan Kastrati, MD*x
Munich and Tübingen, Germany; and Graz, AustriaObjectives This study sought to undertake an updated meta-analysis of randomized trials
investigating the outcomes of percutaneous revascularization with primary drug-eluting stenting in
patients with atherosclerotic disease of infrapopliteal arteries.
Background In atherosclerotic disease of infrapopliteal arteries, drug-eluting stents (DESs) improve
patency rates compared with plain balloon angioplasty or bare-metal stents (BMSs). However, the
clinical impact of DES placement in this vascular territory still remains uncertain.
Methods We searched MEDLINE, Embase, CENTRAL (Cochrane Central Register of Controlled Trials),
scientiﬁc session abstracts, and relevant Websites. The keywords used were “below the knee,”
“infrapopliteal artery,” “angioplasty,” “drug-eluting stent(s),” “bare metal stent(s),” “trial,” and
“randomized trial.” Inclusion criteria were randomized design, intention-to-treat analysis, and
a minimum of 6-month follow-up. Exclusion criteria were vessels treated other than infrapopliteal
arteries; devices used other than DESs, plain balloons, or BMSs; and duplicated data. The primary
endpoint was target lesion revascularization; secondary endpoints were restenosis, amputation, death,
and improvement in Rutherford class.
Results A total of 611 patients from 5 trials were randomly assigned to DESs (n ¼ 294) versus control
therapy (plain balloon angioplasty/BMS implantation, n ¼ 307). Overall, the median lesion length was
26.8 mm (interquartile range [IQR]: 18.2 to 30.0 mm) with a reference vessel diameter of 2.86 mm (IQR:
2.68 to 3.00 mm). At a median follow-up of 12 months (IQR: 12 to 36 months), DESs reduced the risk
of target lesion revascularization (odds ratio [OR]: 0.31; 95% conﬁdence interval [CI]: 0.18 to 0.54;
p < 0.001), restenosis (OR: 0.25; 95% CI: 0.15 to 0.43; p < 0.001), and amputation (OR: 0.50; 95% CI: 0.26
to 0.97); p ¼ 0.04) without a signiﬁcant difference in terms of death (OR: 0.81; 95% CI: 0.45 to 1.49;
p ¼ 0.50) and Rutherford class improvement (OR: 1.36; 95% CI: 0.91 to 2.04; p ¼ 0.13) versus control
therapy.
Conclusions In focal disease of infrapopliteal arteries, DES therapy reduces the risk of reintervention
and amputation compared with plain balloon angioplasty or BMS implantation without any impact on
mortality and Rutherford class at 1-year follow-up. (J Am Coll Cardiol Intv 2013;6:1284–93) ª 2013 by
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1285Endovascular therapy represents the preferred option for
patients with occlusive atherosclerotic disease of infrapopli-
teal arteries requiring revascularization (1). In this setting,
plain balloon angioplasty is still a ﬁrst-line recommendation
due to the high percentage of acute success and relatively low
cost (2,3). In contrast, stent implantation is recommended as
an acute “bail-out” or “salvage” procedure in the event of
a suboptimal result or failure of balloon dilation (2,3).
However, the lack of a proven durable antirestenotic effect
after plain balloon angioplasty has led to the investigation of
alternative strategies (4).See page 1294
Abbreviations
and Acronyms
ARR = absolute risk
reduction
BMS = bare-metal stent(s)
CI = conﬁdence interval
CLI = critical limb ischemia
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
IQR = interquartile range
NNT = number needed to
treat
OR = odds ratio
RC = Rutherford class
TLR = target lesion
revascularizationThe similar vessel diameter of coronary and infrapopliteal
arteries had fueled the use of coronary stent platforms in this
peripheral vascular bed. Several small studies investigated the
angiographic outcomes of drug-eluting stents (DESs)
compared with either plain balloons or bare-metal stents
(BMSs) for revascularization of infrapopliteal arteries (5).
According to available data, primary drug-eluting stenting
demonstrates superior antirestenotic potency compared with
either plain balloons or BMSs with higher patency rates at
mid-term follow-up (6–8). However, the impact of DESs on
clinical outcomes such as repeat revascularization, amputa-
tion, and mortality still remains a matter of uncertainty. On
the one hand, the existing randomized, controlled trials
individually lack the statistical power to discriminate differ-
ences in rare clinical outcomes, and results have been
inconsistent (4). On the other hand, recent meta-analyses
considered only a limited number of the available random-
ized, controlled trials (9,10).
Therefore, the purpose of the present study was to
undertake an updated meta-analysis of randomized trials
investigating outcomes associated with a strategy of percu-
taneous revascularization with primary drug-eluting stenting
in patients with atherosclerotic disease of infrapopliteal
arteries.Methods
Search strategy and selection criteria. We searched MED-
LINE, Embase, CENTRAL (Cochrane Central Register of
Controlled Trials), scientiﬁc sessions abstracts, and relevant
Websites (www.cardiosource.com, www.clinicaltrialresults.
org, www.escardio.org, www.tctmd.com, www.theheart.org)
without restricting language or publication status. The
reference lists from all eligible studies and previously pub-
lished meta-analyses dealing with a similar topic (5,9–11)
were checked to identify further citations. The ﬁnal search
was performed on March 23, 2013. Search terms included
the keywords and the corresponding Medical Subject
Headings for “below the knee,” “infrapopliteal artery,”“angioplasty,” “drug-eluting stent(s),” “bare metal stent(s),”
“trial,” and “randomized trial.” Inclusion criteria were
randomized design, intention-to-treat analysis, and
a minimum of 6 months of follow-up. Exclusion criteria
were vessels treated other than infrapopliteal arteries, devices
used other than DESs, plain balloons, or BMSs, and
duplicated data.
Data collection and assessment of risk of bias. Two inves-
tigators (S.C. and G.N.) independently assessed publica-
tions for eligibility at the title and/or abstract level, with
differences resolved by a third investigator (M.F.). Studies
that met inclusion criteria were selected for further analysis.
Freedom of bias was evaluated for each study by the same
investigators, in accordance with the Cochrane Collabora-
tion method (12) on the basis of the following methodo-
logical items: adequacy of random sequence generation and
allocation concealment, blinding (at participant or outcome
assessor level), completeness of
reporting outcome data, selective
presentation of outcomes, com-
pleteness and adequacy of descrip-
tion of sample size calculation,
and appropriate disclosure of
funding sources. We avoided for-
mal quality score adjudications as
they have previously been found
potentially misleading (13).
Outcome variables. The degree
of restenosis quantiﬁes the res-
ponse of the vessel wall to in-
terventions (14) and may not be
synonymous of revascularization
(15). The primary outcome of
the present study was target
lesion revascularization (TLR)
driven from clinical symptoms as
well as from invasive surveillance.
Secondary outcomes were restenosis, amputation, Ruth-
erford class (RC) improvement, and death. All endpoints
were evaluated at the longest available follow-up according
to per-protocol deﬁnitions: the most updated or most
inclusive data for a given study were analyzed. Where further
details were required, we attempted to obtain them from the
study investigators directly. However, we did not request
patient-level data from the investigators of original studies.
Statistical analysis. Statistical analysis was performed using
the RevMan (Review Manager [RevMan] Version 5.1, The
Cochrane Collaboration, Copenhagen, Denmark), and Stata
version 11.2 (StataCorp, College Station, Texas) software
packages.
The l statistic was used to assess agreement between
reviewers for study selection. Odds ratio (OR) and 95%
conﬁdence interval (CI) were used as summary statistics and
were derived for comparison of DESs and pooled plain
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1286balloons/BMSs (the control therapy). To test whether the
pooling of plain balloons and BMSs as control therapy
affected the analysis of the main outcomes, the risk estimates
associated with DES therapy were also calculated after
stratiﬁcation for plain balloons or BMSs as the control arm.
The Mantel-Haenszel random-effects model (DerSimonian
and Laird) was used to calculate pooled OR for categorical
variables (16). In the case of statistical signiﬁcance, absolute
risk reduction (ARR) and the number needed to treat
(NNT) with 95% CI were provided. The Breslow-Day
chi-square test and the I2 statistic were used to test het-
erogeneity across the studies. As a guide, I2 values <25%
indicated low, 25% to 50% moderate, and >50% high
heterogeneity (12). To estimate the additive (between-study)
component of variance, the restricted maximum likelihood
method (Tau2) took into account the occurrence of residual
heterogeneity. Visual estimation of funnel plots as well as
statistical tests assessed possible publication bias for primary
outcome (17–19). Similarly, an inﬂuence analysis, in which
meta-analysis estimates are computed omitting 1 study at
a time, was performed for primary outcome. A random-
effects sensitivity analysis evaluated the extent to which
several covariatesdtrial size, length of clinical follow-up,
protocol-mandated angiography, lesion length, vessel
diameter, and length of dual antiplatelet therapy
(DAPT)dmight have inﬂuenced the risk estimates for the
primary outcome. A random-effects meta-regression analysisFigure 1. PRISMA Flow Chart for the Trial Selection Process
Control arm included patients treated with plain balloon angioplasty or BMS.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); PRISMA ¼ Preferred Reporting
trial.assessed the relationship between the baseline disease
severity (expressed as the proportion of patients with critical
limb ischemia [CLI] or with infrapopliteal artery occlusions
and the mean length of the lesions) and the risk estimates for
TLR. Two adjusted indirect comparisons according to the
method of Bucher et al. (20) and Song et al. (21) investi-
gated whether the various DES platforms included in the
experimental arm (everolimus- vs. sirolimus-eluting stents;
polymer-free vs. durable-polymer DESs) provided differ-
ences in the main outcomes.
This study was performed in compliance with the
PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) statement (22).
Results
Eligible studies. The process of trial selection is summarized
in Figure 1. We excluded the trial of Rand et al. (23) because
it investigated the outcomes of patients randomly assigned
to carbon ﬁlm–coated BMS implantation versus plain
balloon angioplasty. Finally, 5 trials (6–8,24,25), all with
full-length reports, were selected. In the DES and BMS
arms of original studies, pre-dilation was allowed before
stent implantation, whereas patients in the plain balloon arm
received no therapy other than plain balloon angioplasty.
Thus, for the current analysis, the control therapy comprised
patients treated with BMS implantation (with or withoutItems for Systematic reviews and Meta-Analyses; RCT ¼ randomized, controlled
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1287pre-dilation) and patients receiving plain balloon angioplasty
alone. One trial had a 4-arm design and randomly assigned
patients to DES implantation or plain balloon angioplasty or
BMS implantation after a pre-treatment with a glycopro-
tein IIb/IIIa inhibitor (abciximab) versus plain balloon
angioplasty alone (25). For the purpose of this meta-analysis,
the outcome data from the plain balloon and BMS arms of
this trial were grouped to derive pooled estimates. One trial
(26) recently reported long-term outcomes, which were
included in the present analysis. Thus, a total of 611 patients
(294 randomized to DES therapy and 307 to control
therapy) were studied. Interobserver agreement for study
selection was very good, with a l value of 0.95.
The main characteristics of the studies included are
described in detail in Table 1. Three (6–8) of 5 trials had
a multicenter design. Patients with evidence of >50% to
70% stenosis or occlusion of the infrapopliteal arteries and
with symptoms from disabling intermittent claudication to
CLI were randomized to percutaneous revascularization with
DESs versus control therapy. Patients presenting with an RC
of 3 to 5 (6–8,24) or 6 (25) were enrolled in trials. One trial
included 10 patients (6.2%) with an RC of 2 at admission (6).
Patients with acute limb ischemia, untreated in-/outﬂow
lesions or aneurysms, and previous stenting of the target
lesion were excluded. Among trials comparing DES therapy
and plain balloon angioplasty, few cases treated by balloon
required crossover to provisional stenting due to a suboptimal
initial result after angioplasty (7,25). Protocol-mandated
angiography was performed in 4 (7,8,24,25) of 5 trials.
Patients enrolled in the DES arms received limus-eluting
stents approved for coronary interventions (sirolimus-eluting
stent [6,7,24,25] [Cypher or Cypher Select, Cordis, Johnson
& Johnson, Bridgewater, New Jersey; Yukon DES, Trans-
lumina, Hechingen, Germany]; everolimus-eluting stent [8]
[Xience V, Abbott Laboratories, Abbott Park, Illinois]).
Patients enrolled in the BMS arms received conventional
316L stainless steel stents (Bx-Velocity [25] or Sonic [24],
Cordis, Johnson & Johnson) or microstructured 316L
stainless steel, microporous stents (6) (Yukon, Translumina)
or 605L cobalt-chromium, thin-strut stents (8) (Multilink
Vision, Abbott Laboratories, Abbott Park, Illinois).
The median number of patients included in the trials
was 140 (interquartile range [IQR]: 60 to 161) and their
clinical characteristics matched typical patients with infra-
popliteal artery disease (Table 2). Overall, the median
lesion length was 26.8 mm (IQR: 18.2 to 30.0 mm) with
a reference vessel diameter of 2.86 mm (IQR: 2.68 to
3.00 mm). More speciﬁcally, patients undergoing DES
implantation had a median lesion length of 26.9 mm
(IQR: 17.4 to 27.0 mm) and a reference vessel diameter of
2.90 mm (IQR: 2.69 to 3.00 mm). Patients receiving
control therapy had a median lesion length of 26.8 mm
(IQR: 18.9 to 30.0 mm) and a reference vessel diameter of
2.83 mm (IQR: 2.68 to 2.91 mm).An overview of endpoint deﬁnitions among trials
included is reported in Online Table 1. In all cases but 1
(25), the primary endpoint was binary restenosis at 6- or 12-
month follow-up. The remaining trial primarily evaluated
the rate of target-vessel reocclusion at 2-month follow-up.
All patients received active or control treatment in addition
to standard medical therapy. Details of post-procedural
antiplatelet management and prescription were available in
all trials. Median duration of DAPT was 12 months (IQR:
12 to 36 months).
The risk of bias among studies is reported in Online
Table 2. Of those randomized, 589 patients (96.3%)
were available for assessment of outcomes of interest.
The median follow-up was 12 months (IQR: 12 to 36
months).
Outcomes. TLR occurred in 97 patients (17.5%; data
available for 554 [94%] patients, all trials). DES versus
control therapy signiﬁcantly decreased the risk of TLR (OR:
0.31; 95% CI: 0.18 to 0.54; p < 0.001; I2 ¼ 15%, p for
heterogeneity [phet] ¼ 0.32; ARR: 15.5%; 95% CI: 9.3 to
21.6; NNT: 7; 95% CI: 5 to 11) (Fig. 2A).
Restenosis occurred in 183 patients (36.4%; data available
for 502 patients [85%], all trials). DES versus control
therapy signiﬁcantly decreased the risk of restenosis (OR:
0.25; 95% CI: 0.15 to 0.43; p < 0.001; I2 ¼ 38%, phet ¼
0.17; ARR: 29.6%; 95% CI: 21.7 to 37.6; NNT: 4; 95% CI:
3 to 5) (Fig. 2B).
Amputation occurred in 52 patients (10.3%; data available
for 504 patients [85.6%], 4 trials [6–8,25]). DES versus
control therapy signiﬁcantly decreased the risk of amputa-
tion (OR: 0.50; 95% CI: 0.26 to 0.97; p ¼ 0.04; I2 ¼ 0%,
phet ¼ 0.61; ARR: 7.5%; 95% CI: 2.2 to 12.7; NNT: 13;
95% CI: 8 to 45) (Fig. 2C).
Death occurred in 96 patients (16.2%) (data available for
all patients). No signiﬁcant difference in terms of risk of
death was found with DES therapy compared with control
therapy (OR: 0.81; 95% CI: 0.45 to 1.49; p 0.50; I2 ¼ 32%;
phet ¼ 0.22) (Fig. 2D).
An improvement in RC occurred in 246 patients (55%;
data available for 448 patients [76%], 3 trials [6–8]). No
signiﬁcant difference in terms of RC improvement was
found with DES therapy compared with control therapy
(OR: 1.36; 95% CI: 0.91 to 2.04; p ¼ 0.13; I2 ¼ 6%, phet ¼
0.34) (Fig. 2E).
DES therapy compared with either plain balloon angio-
plasty or BMS implantation signiﬁcantly decreased the risk
of TLR, restenosis, and amputation without affecting
mortality or improving RC (Online Table 3).
Small study effects, inﬂuence, and sensitivity analyses.
Funnel plot distribution of primary outcomes was derived
from the SE of the natural logarithm OR plotted against the
OR of TLR (Online Fig. 1A). Of note, the absence of
bias due to small study effects was conﬁrmed both visually
and mathematically. Additionally, the inﬂuence analysis
Table 1. Main Characteristics of Trials Included in the Study
Trial/First
Author (Ref. #) Years Inclusion Criteria Exclusion Criteria Primary Endpoint Secondary Endpoints DES
Registration
No.
ACHILLES
(7)
2008–2010 Age 18 and 85 yrs; Rutherford
classes 3–5; de novo or restenotic
(after PTA only) lesions; maximum
2 diseased vessels in 1 limb; 4
stents required to fully cover the
lesions; occlusion or stenosis
70% of vessel diameter; 2.5-
and 3.5-mm reference vessel
diameter; 120 mm in length;
successful guidewire passage
Outﬂow free of stenosis >50%;
angiographic evidence of
thrombus; thrombolysis 72 h
before procedure; untreated
signiﬁcant (>75%) inﬂow lesions;
previous stenting of the target
lesion; target lesion requiring
bifurcation stenting; MI, stroke, or
coronary intervention <30 days
before the index procedure;
1 year life expectancy
12-month in-
segment binary
restenosis
Technical and
procedural success;
12-month percentage
of diameter stenosis;
12-month in-segment
and in-stent LLL; TLR;
6-week, 6-, and
12-month patency;
6-week, 6-, and
12-month TLR; TVR;
change in mean ABI
and Rutherford class,
amputations, serious
adverse events,
wound status (if
applicable)
Cypher
Select*
NCT00640770
BELOW (25) 2003–2006 Age 18 and 95 yrs; Rutherford
classes 5 and 6; maximum of 3
lesions in 1 vessel; 2 stents
required to fully cover the lesions;
occlusion or stenosis 70% vessel
diameter; 50 mm in length;
successful guidewire passage
Outﬂow free of stenosis >50% or
aneurysms within 30 mm of the
target lesion; acute limb ischemia
or limb ischemia requiring
thrombolysis before intervention;
active bleeding; known
abciximab-induced
thrombocytopenia; major surgery,
eye surgery or trauma 6 wks
before index procedure; 1 yr life
expectancy
2-month target
vessel
reocclusion
Technical success;
6-month binary
restenosis rate; 2- and
6-month mortality,
amputation, TVR,
change in mean ABI
and Rutherford class,
wound healing, QOL
Cypher* NCT00163254
DESTINY (8) 2008–2010 Age 18 yrs; Rutherford classes 4
and 5; de novo or restenotic (after
PTA only) lesions; maximum of 2
lesions in 1 vessel; 2 stents
required to fully cover the lesions;
>50% of vessel diameter; 2.0-
and 3.5-mm reference vessel
diameter; 50 mm in length;
successful guidewire passage;
inﬂow free of unsuccessfully
treated lesion (>30% residual
stenosis)
Buerger disease; reference vessel
diameter not suitable for stent
platforms selected; <1 outﬂow
vessel; untreated signiﬁcant
inﬂow lesions or aneurysms;
previous stenting of the target
lesion; target lesion requiring
kissing stenting; active bleeding
or malignancy requiring
anticancer therapy <30 days
before or after index procedure;
1 yr life expectancy
12-month in-stent
binary
restenosis
Technical success; 12-
month clinical
success (1
Rutherford class
improvement),
primary patency, limb
salvage rate, serious
adverse events
XIENCE
Vy
NCT00510393
Falkowsky
et al. (24)
2009–2010 Age 30 yrs, Rutherford classes 3–5;
de novo lesions; occlusion or
stenosis >60% of vessel diameter;
2.0- and 3.5- mm reference
vessel diameter; 5 to 30 mm
in length; successful guidewire
passage
Buerger disease; <1 outﬂow vessel;
untreated signiﬁcant inﬂow
lesions or aneurysms; previous
intervention of the target limb;
active bleeding or malignancy;
other intervention performed
<30 days before or after index
procedure; 1 yr life expectancy
6-month in-stent
binary
restenosis
Technical and
procedural success;
6-month percentage
of diameter stenosis,
in-stent LLL, TLR, and
ABI
Cypher* N/A
YUKON-BTK
(6)
2006–2008 Age 18 yrs; Rutherford classes 3–5;
de novo lesions; 2 stents
required to fully cover the lesions;
>70% of vessel diameter; 2.5-
and 3.5-mm reference vessel
diameter; 45 mm in length;
successful guidewire passage;
inﬂow free of unsuccessfully
treated lesion (>30% residual
stenosis)
Buerger disease; outﬂow free of
stenosis >50%; angiographic
evidence of thrombus;
thrombolysis 72 h before
procedure; untreated signiﬁcant
(>75%) inﬂow lesions; previous
stenting of the target lesion;
target lesion requiring bifurcation
stenting; MI, stroke, or coronary
intervention <30 days before
index procedure; 1 yr life
expectancy
12-month binary
restenosis
6-month primary
patency rate;
12-month secondary
patency rate;
12-month death,
amputation, TLR, and
MI incidence
Yukon
DESz
NCT00664963
ABI ¼ ankle-brachial index; DES ¼ drug-eluting stent(s); LLL ¼ late lumen loss; MI ¼ myocardial infarction; N/A ¼ not available; PTA ¼ percutaneous transluminal angioplasty; QOL ¼ quality of life;
TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization. *Cordis, Johnson & Johnson, Bridgewater, New Jersey. yAbbott Laboratories, Abbott Park, Illinois. zTranslumina, Hechingen,
Germany.
Trial acronyms: ACHILLES ¼ Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease; BELOW ¼ Balloon angioplasty or Stents With ReoPro for
Prevention of Subacute Reocclusion in Arteries Below the Knee Angioplasty; DESTINY ¼ Drug Eluting Stents In The Critically Ischemic Lower Leg; YUKON-BTK ¼ YUKON-Drug-Eluting Stent Below The
Knee.
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Table 2. Main Characteristics of Patients Enrolled Among Trials Included in the Study
Trial/First
Author (Ref. #) No. of Patients Age, yrs Males, % Diabetes, % CLI, % Occlusion % Lesion length, mm Vessel Diameter, mm DAPT, mo
Longest
FU, months
ACHILLES (7) 200 73.4 71 65 N/A 78.3 26.9 2.60 6 12
BELOW (25) 60 72.4 64 68 100 32.6 27.0 2.90 2 36
DESTINY (8) 140 75.5 64 55 100 16.0 15.9 3.00 12 12
Falkowski et al. (24) 50 69.4 58 66 32 N/A 17.8 2.69 6 6
YUKON-BTK (6) 161 72.9 67 54 47 22.4 30.0 3.00 6 50
Overall mean values are reported.
Trial acronyms as in Table 1.
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1289demonstrated that no single study signiﬁcantly altered the
summary OR for TLR (Online Fig. 1B).
There was no modiﬁcation of risk estimates for TLR
according to trial size, length of clinical follow-up, proto-
col-mandated angiography, lesion length, vessel diameter,
and length of DAPT (Fig. 3). Similarly, the degree of
baseline disease severity did not affect the risk estimates for
TLR (Online Figs. 2A to 2C). On adjusted indirect
comparison (Online Table 4), the everolimus- versus siroli-
mus-eluting stents, as well as the polymer-free versus
durable-polymer DESs did not affect the risk estimates for
the main outcomes.
Discussion
We undertook this updated meta-analysis to investigate the
outcomes associated with primary drug-eluting stenting for
percutaneous revascularization of patients with atheroscle-
rotic disease of infrapopliteal arteries. The main ﬁndings are
that at 1-year follow-up, DES therapy demonstrated
reduced restenosis and greater clinical efﬁcacy compared
with plain balloon angioplasty or BMS therapy with
a reduced risk of reintervention and amputation, although
a lack of RC improvement and DESs have a safety proﬁle
comparable to that of alternative therapy, with no impact on
mortality.
Patients with atherosclerotic disease of infrapopliteal
arteries represent an important challenge due to compro-
mised functional status, coexisting morbidities, and poor
outcomes (1). In this context, endovascular revascularization
has become a ﬁrst-line treatment option in light of superior
feasibility and similar efﬁcacy compared with surgical repair
(2,3,11). Although in the past decades, percutaneous
revascularization has become synonymous with stenting, in
infrapopliteal artery disease, plain balloon angioplasty
remains the treatment of choice due to the diffuse nature of
infrapopliteal atherosclerosis and the lack of data deﬁnitively
supporting a stent-based strategy in this vascular bed (2,3).
In recent studies, BMSs have shown almost similar
survival, limb salvage, and patency rates compared with plain
balloon angioplasty at 1-year follow-up (5,23). In a meta-
analysis of observational studies evaluating bail-out stentingafter failed angioplasty (5), stents signiﬁcantly improved
patency rates at mid-term follow-up without affecting the
risk of TLR and amputation. Although different stent
scaffolds (balloon expandable, self-expandable, bio-
absorbable) and types of stents (bare metal, carbon coated,
drug eluting) contributed to the outcome data, the highest
antirestenotic efﬁcacy was attributable to DESs (5).
Initial data from observational registries (27,28) as well as
subsequent randomized trials (6–8) consistently showed less
neointimal proliferation at mid-term follow-up after DES
implantation versus plain balloon angioplasty or BMS
implantation in patients with infrapopliteal artery disease
treated percutaneously. However, the superior antirestenotic
properties of DESs did not always translate into a meaningful
clinical advantage. In a meta-analysis of 3 randomized trials,
Katsanos et al. (9) conﬁrmed the antiproliferative efﬁcacy of
DESs for atherosclerotic disease of the infrapopliteal arteries.
However, RC improvement, nor amputation, nor mortality
beneﬁts were found, suggesting a possible discrepancy
between mechanistic and clinical measures of efﬁcacy in this
setting.Antoniou et al. (10) conducted ameta-analysis of both
randomized and observational studies investigating onlyDES
versus BMS therapy for disease of infrapopliteal arteries. The
authors concluded that DES therapy reduces the risk of
reintervention and improves RC without affecting amputa-
tion and survival. As a consequence, given the lack of incon-
trovertible evidence, current guideline-writing authorities still
assign the highest grade of recommendation to plain angio-
plasty in patients with infrapopliteal atherosclerotic disease,
leaving stents with a “bail-out” or “salvage” indication after
failed angioplasty (2,3).
Against this background, we conducted the present meta-
analysis to investigate the impact of primary drug-eluting
stenting in the largest population of patients with occlusive
infrapopliteal atherosclerotic disease undergoing percuta-
neous revascularization in the context of randomized trials:
at 1-year follow-up, DES therapy compared with plain
balloon angioplasty and BMS therapy reduced the risk of
reintervention and amputation with no impact on mortality
and RC. These results merit careful consideration.
First, the present study reports a lower risk of restenosis
and reintervention at 1-year follow-up with DES therapy
Figure 2. Risk Estimates of Primary and Secondary Outcomes for DES Therapy Versus Control Therapy
Plot of odds ratio for primary (A) and secondary (B to E) outcomes associated with DES therapy versus control therapy. The diamond indicates the point estimate and
the left and the right ends of the line show the 95% conﬁdence interval (CI). DES ¼ drug-eluting stent(s); M-H ¼ Mantel-Haenszel. Trial acronyms: ACHILLES ¼
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease; BELOW ¼ Balloon angioplasty or Stents With ReoPro for
Prevention of Subacute Reocclusion in Arteries Below the Knee Angioplasty; DESTINY ¼ Drug Eluting Stents In The Critically Ischemic Lower Leg; YUKON-BTK ¼
YUKON-Drug-Eluting Stent Below The Knee. Continued on the next page.
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important drawback of plain balloon angioplasty or BMS
therapy in the infrapopliteal vascular territory is the poor
durability of acute results due to vessel re-narrowing after
intervention (29). In this respect, the ﬁnding of reduced
rates of TLR with DES therapy at 1-year follow-up, in
keeping with published meta-analyses (9,10), is an impor-
tant one. Of interest, 4 of the 5 trials included in the present
meta-analysis (6,7,24,25) found no difference in terms ofTLR between DESs and comparators. This is most likely
attributable to design of original studies, which contained
only sufﬁcient power for angiographic rather than rarer
clinical outcomes, and reinforces the necessity of a meta-
analysis.
In this study, the observed beneﬁt of DES therapy versus
plain balloon angioplasty or BMS therapy in terms of TLR
is independent from trial size, length of clinical follow-
up, protocol-mandated angiography, lesion length, vessel
Figure 2. Continued
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standing, some safety considerations exist regarding the risk
of DES thrombosis due to suboptimal duration of DAPT
(30), and dedicated trials are awaited to ascertain the
contribution of duration of DAPT to the safety and efﬁcacy
of DES for infrapopliteal arteries.
Second, in contrast to the meta-analysis of Katsanos et al.
(9), we demonstrated that DESs are associated with a
signiﬁcant reduction in the risk of amputation at 1-year
follow-up. As many as 50% of patients with infrapopliteal
artery occlusive disease may require amputation at various
levels within the ﬁrst year after the diagnosis, especially in
those patients presenting with CLI (1,31). As known, less
perfusion is needed to maintain tissue integrity than to avoid
amputation: for this reason, restenosis does not always result
in recurrent symptoms unless there has been repeated injury
of the affected limb (32). Assessing prevention of amputation
rather than angiographic patency should become the main
goal of trials investigating revascularization of the infrapo-
pliteal arteries (32). In line with these arguments, the lower
risk of amputation and the higher antirestenotic efﬁcacy
associated with DESs in the current analysis are remarkable,
especially when a last remaining infrapopliteal vessel must be
preserved to warrant straightforward distal perfusion.
In the current study, the use of DES therapy versus plain
balloon angioplasty or BMS therapy has no impact on
mortality. On the one hand, this analysis conﬁrms that thesuperior clinical efﬁcacy of DES therapy versus plain balloon
angioplasty or BMS therapy has no trade-off in safety. On
the other hand, even reducing reinterventions and amputa-
tions, a strategy of primary percutaneous revascularization
with DESs is still not sufﬁcient to lower the intrinsic
mortality risk associated with patients with atherosclerotic
disease of infrapopliteal arteries (2). The possible inadequacy
of the sample size and the selective nature per se of patients
enrolled in randomized trials could be responsible for the lack
of effect. In addition, pre-existing comorbidities, as well as
poor functional status, 2 common features of patients with
infrapopliteal artery disease (32), may have further contrib-
uted to mask signiﬁcance. Similarly, these features may
account for the failure of DES therapy compared with control
therapy to signiﬁcantly improve RC, although lowering the
risk of revascularization and amputation as observed in the
present study. Taken together, all these considerations rein-
force the necessity of more deserved investigations in this
setting to address the portfolio of therapeutic options, other
than the revascularization strategies, should be reserved for
patients with infrapopliteal artery disease (33).
Study limitations. The present study included a total of
611 patients by pooling the results of 5 randomized
trials enrolling patients with infrapopliteal artery disease.
Although the number of trials and patients is relatively
small, it represents the largest population analyzed in such
studies. However, it presents some limitations. First, this
Figure 3. Sensitivity Analyses of Primary Outcome for DES Therapy Versus Control Therapy
Plot of odds ratio (OR) for target lesion revascularization associated with DES therapy versus control therapy in subgroups of interest. The diamond indicates the point
estimate and the left and the right ends of the line show the 95% CI for the overall population. The squares indicates the point estimate, and the left and the right
ends of the line give the 95% CI for the subgroup of interest. The I2 statistic describes heterogeneity across trials included resulting after adjusted indirect comparison.
DAPT ¼ dual antiplatelet therapy; pint ¼ p values for interaction between treatment effect and subgroups derived by meta-regression analysis; other abbreviations as
in Figure 2.
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possible ﬂaws of the original trials. Moreover, the lack of
patient-level data precluded in-depth investigation of the
planned/unplanned nature of amputations. Second, different
devices are grouped in the experimental and control arms,
even though efﬁcacy proﬁles may vary between platforms and
devices. Furthermore, none of the included trials considered
newer-generation balloons coated with antiproliferative
drugs. Third, the median follow-up is limited to 1 year.
Longer-term follow-up would certainly be valuable in
assessing the late clinical performance of revascularization
strategies. Fourth, the protocol-mandated angiography may
have magniﬁed differences in absolute proportion of revas-
cularizations across groups, although the relative differences
are likely to remain unaffected. Notwithstanding the possible
inﬂuence of protocol-mandated angiography on revasculari-
zations, available data showed that most of repeat procedures
were driven by clinical symptoms. Finally, the population
included in this analysis, reporting disabling claudication as
well as CLI, with an overall median lesion length of 26.8 mm
and a reference vessel diameter of 2.86 mm, could be
perceived as not representative of that encountered in daily
practice, often presenting with very diffuse disease (>10 cm)
and very extensive wounds. For these reasons, the present
ﬁndings should apply only to patients with characteristicssimilar to those enrolled in this study and presenting with
focal lesions.
Conclusions
This meta-analysis suggests that in patients with focal
disease of infrapopliteal arteries, DES therapy reduces the
risk of reintervention and amputation compared with plain
balloon angioplasty or BMS therapy without any impact on
mortality and RC at 1-year follow-up. Further randomized
trials with a focus on clinical endpoints and longer follow-up
are still awaited to provide the best scientiﬁc evidence
regarding the preferred endovascular treatment for patients
with occlusive disease of infrapopliteal arteries.
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